Compare BEDU & NOTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BEDU | NOTV |
|---|---|---|
| Founded | 1994 | 1974 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.0M | 29.9M |
| IPO Year | 2017 | 1997 |
| Metric | BEDU | NOTV |
|---|---|---|
| Price | $2.19 | $0.81 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 4.6K | ★ 1.6M |
| Earning Date | 01-23-2026 | 12-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $224,321,752.00 | ★ $513,024,000.00 |
| Revenue This Year | N/A | $6.26 |
| Revenue Next Year | N/A | $45.49 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 4.54 |
| 52 Week Low | $1.35 | $0.66 |
| 52 Week High | $2.28 | $6.48 |
| Indicator | BEDU | NOTV |
|---|---|---|
| Relative Strength Index (RSI) | 57.57 | 36.67 |
| Support Level | $2.14 | $0.84 |
| Resistance Level | $2.22 | $0.95 |
| Average True Range (ATR) | 0.03 | 0.12 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 43.75 | 39.36 |
Bright Scholar Education Holdings Ltd operates as an education service provider. It is engaged in the provision of education services, including complementary education services, operation services for domestic schools, and education programs and services including independent schools and colleges in United Kingdom and the United States. It nearly eight overseas school located in the United Kingdom and the United States. It has three reportable segments, including Overseas Schools, Complementary Education Services, and K-12 Operation Services. Key revenue is generated from Overseas Schools. From a geographical perspective: Key revenue is generated from China following UK, U.S., Canada and Singapore.
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.